Concepta is a company that makes the MyLotus fertility monitor, designed to help women who are trying to get pregnant.
As of 15th July, the company has market cap of £7.8m and 2018 revenues were negligible as the product was not yet launched.
However, in 2019 they have properly launched MyLotus, have got it listed in Boots, sell it on Amazon and also have apps available to help with fertility track in the iOS App Store and the Google App Store. I could not find any recent broker forecasts, but Stockopedia has forecast revenue of £14.3m and net for profit of £2.29m putting it on a PE of 1.4 – but it looks like these are out of date so would not rely on them.
This has been a bit of ‘jam tomorrow’ stock, with promises of product breakthroughs and meaningful revenues have been predicted for a while but never materializing. It has been tipped a number of times by Shareprophets / HotStockRockets but remains one of a number of Adam Reynolds’ companies that makes a lot of noise but never really gets anywhere (Optibiotix is another that springs to mind).
The latest announcement from Concepta on 9th July says that pregnancies from MyLotus are now in double figures. We have been trying to track sales / app downloads over the past few months and our research doesn’t fill us with hope of meaningful revenue:
Cumulative Reviews of MyLotus Product
|Number of Reviews||29/03/2019||25/04/2019||14/05/2019||07/06/2019||02/07/2019||15/07/2019|
|Amazon Reviews – 3 SKUs||0||0||0||0||0||1|
|Boots Reviews – 3 SKUs||0||0||0||0||0||2|
|Google App Store Reviews||1||1||2||2||2||2|
|iOS App Store Reviews||3||4||4||4||4||4|
A total of 9 reviews over 3.5 months appears poor for a company that has a £7.8m market cap. The number of reviews may be low as it is a private product/topic and people perhaps don’t want to write about it in public, but there is always the option to post an anonymous review.
To us, this looks like the next set of results will disappoint and if holding would be looking to sell.